BR112016009665A8 - polimorfos, composição farmacêutica, processos para a preparação de um polimorfo e usos dos polimorfos - Google Patents
polimorfos, composição farmacêutica, processos para a preparação de um polimorfo e usos dos polimorfos Download PDFInfo
- Publication number
- BR112016009665A8 BR112016009665A8 BR112016009665A BR112016009665A BR112016009665A8 BR 112016009665 A8 BR112016009665 A8 BR 112016009665A8 BR 112016009665 A BR112016009665 A BR 112016009665A BR 112016009665 A BR112016009665 A BR 112016009665A BR 112016009665 A8 BR112016009665 A8 BR 112016009665A8
- Authority
- BR
- Brazil
- Prior art keywords
- polymorphs
- processes
- preparation
- polymorph
- pharmaceutical composition
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 abstract 3
- 229950001269 taselisib Drugs 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
a presente invenção se refere aos polimorfos cristalinos de (2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)-5,6-diidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)-1h-pirazol-1-il)-2-metilpropanamida (gdc-0032, taselisib), aos seus métodos de utilização e aos seus processos de preparação.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361916657P | 2013-12-16 | 2013-12-16 | |
| PCT/EP2014/077666 WO2015091305A1 (en) | 2013-12-16 | 2014-12-15 | Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016009665A8 true BR112016009665A8 (pt) | 2020-04-07 |
Family
ID=52023532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016009665A BR112016009665A8 (pt) | 2013-12-16 | 2014-12-15 | polimorfos, composição farmacêutica, processos para a preparação de um polimorfo e usos dos polimorfos |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9266903B2 (pt) |
| EP (1) | EP3083640A1 (pt) |
| JP (2) | JP6302089B2 (pt) |
| KR (2) | KR101902664B1 (pt) |
| CN (2) | CN109293674A (pt) |
| AR (1) | AR098762A1 (pt) |
| AU (3) | AU2014365079B2 (pt) |
| BR (1) | BR112016009665A8 (pt) |
| CA (1) | CA2927125A1 (pt) |
| HK (1) | HK1223101A1 (pt) |
| IL (2) | IL244915A0 (pt) |
| MX (1) | MX356804B (pt) |
| RU (2) | RU2018119749A (pt) |
| SG (3) | SG10201705669QA (pt) |
| TW (2) | TW201731852A (pt) |
| WO (1) | WO2015091305A1 (pt) |
| ZA (1) | ZA201602534B (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107635560A (zh) * | 2015-06-29 | 2018-01-26 | 豪夫迈·罗氏有限公司 | 用他塞利昔布进行治疗的方法 |
| TWI795344B (zh) * | 2015-06-30 | 2023-03-11 | 美商建南德克公司 | 含藥物之立即釋放錠劑及形成該錠劑的方法 |
| WO2018197653A1 (en) | 2017-04-28 | 2018-11-01 | F. Hoffmann-La Roche Ag | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production |
| EP3687992A1 (en) * | 2017-09-27 | 2020-08-05 | Meiji Seika Pharma Co., Ltd. | Crystalline forms of diazabicyclooctane derivatives and production process thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011036280A1 (en) * | 2009-09-28 | 2011-03-31 | F. Hoffmann-La Roche Ag | Benzoxazepin pi3k inhibitor compounds and methods of use |
| CN104379163A (zh) * | 2012-06-08 | 2015-02-25 | 霍夫曼-拉罗奇有限公司 | 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合 |
| WO2014140073A1 (en) * | 2013-03-13 | 2014-09-18 | F. Hoffmann-La Roche Ag | Process for making benzoxazepin compounds |
-
2014
- 2014-12-15 CN CN201811256901.1A patent/CN109293674A/zh active Pending
- 2014-12-15 EP EP14811921.7A patent/EP3083640A1/en not_active Withdrawn
- 2014-12-15 MX MX2016007581A patent/MX356804B/es active IP Right Grant
- 2014-12-15 SG SG10201705669QA patent/SG10201705669QA/en unknown
- 2014-12-15 BR BR112016009665A patent/BR112016009665A8/pt not_active Application Discontinuation
- 2014-12-15 KR KR1020167015862A patent/KR101902664B1/ko active IP Right Grant
- 2014-12-15 KR KR1020187023324A patent/KR20180093138A/ko not_active Application Discontinuation
- 2014-12-15 AU AU2014365079A patent/AU2014365079B2/en not_active Ceased
- 2014-12-15 CA CA2927125A patent/CA2927125A1/en not_active Abandoned
- 2014-12-15 SG SG10201705673QA patent/SG10201705673QA/en unknown
- 2014-12-15 WO PCT/EP2014/077666 patent/WO2015091305A1/en active Application Filing
- 2014-12-15 RU RU2018119749A patent/RU2018119749A/ru unknown
- 2014-12-15 RU RU2016127039A patent/RU2658009C2/ru not_active IP Right Cessation
- 2014-12-15 US US14/570,019 patent/US9266903B2/en active Active
- 2014-12-15 CN CN201480068672.4A patent/CN105829323B/zh active Active
- 2014-12-15 JP JP2016558275A patent/JP6302089B2/ja active Active
- 2014-12-15 TW TW105143616A patent/TW201731852A/zh unknown
- 2014-12-15 SG SG11201604903VA patent/SG11201604903VA/en unknown
- 2014-12-15 TW TW103143724A patent/TWI638818B/zh not_active IP Right Cessation
- 2014-12-15 AR ARP140104667A patent/AR098762A1/es unknown
-
2016
- 2016-01-08 US US14/991,658 patent/US9481690B2/en active Active
- 2016-04-05 IL IL244915A patent/IL244915A0/en unknown
- 2016-04-14 ZA ZA201602534A patent/ZA201602534B/en unknown
- 2016-09-29 HK HK16111381.6A patent/HK1223101A1/zh unknown
- 2016-11-14 IL IL248965A patent/IL248965A0/en unknown
-
2017
- 2017-06-06 AU AU2017203817A patent/AU2017203817B2/en not_active Ceased
- 2017-06-06 AU AU2017203819A patent/AU2017203819B2/en not_active Ceased
- 2017-12-20 JP JP2017244553A patent/JP2018080179A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2958289B1 (fr) | Procede de preparation de derives de 3-ceto-benzofurane | |
| FR2991320B1 (fr) | Procede de preparation d'amines methylees | |
| BR112014028395A2 (pt) | derivados 3,4-di-hidro-2h-pirido[1,2-a] pirazina-1,6-diona substituídos úteis para o tratamento de (inter alia) doença de alzheimer | |
| BR112015020716A2 (pt) | processo para a preparação de (2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)-5,6-diidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)-1h-pirazol-1-il)-2-metilpropanamida (i) e composto | |
| FR2963006B1 (fr) | Procede de preparation de derives de nitro-benzofurane | |
| FR2958290B1 (fr) | Procede de preparation de derives de sulfonamido-benzofurane | |
| FR2962731B1 (fr) | Procede de preparation de derives d'amino-benzoyl-benzofurane | |
| BR112014006482A2 (pt) | uso de derivados de isossorbida para produção de preparações cosméticas | |
| WO2014155300A3 (en) | Substitued pyrimidine amine derivatives as tak-1 inhibitors | |
| ES2980505T3 (es) | Procedimiento para la preparación de un inhibidor de PDE4 | |
| IL281087A (en) | Process for preparing (S)-2-((2-((S)-4-(difluoromethyl)-2-oxoxazolidine-3-YL)-6,5-dihydrobenzo[F]imidazo[2,1-D][4 , 1]oxazapine-9-YL)amino)propanamide | |
| UY35746A (es) | Derivados de fenilalanina sustituidos | |
| DK3083627T3 (da) | [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis | |
| BR112016009665A8 (pt) | polimorfos, composição farmacêutica, processos para a preparação de um polimorfo e usos dos polimorfos | |
| WO2013128379A3 (en) | Crystalline polymorphic forms of linagliptin | |
| TN2013000420A1 (en) | 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors | |
| HK1201060A1 (zh) | -二甲基苯基 -丙醛的製備方法 | |
| BR112012016816A2 (pt) | derivados de 5-oxo-5,8-di-hidro-pirido[2,3-d] pirimidina como inibidores de quinases camkii para o tratamento de doencas cardiovasculares | |
| FR2999180B1 (fr) | Procede de preparation de sels d'imidazolium dissymetriques | |
| EP3398946A4 (en) | SALT OF MORPHOLINE DERIVATIVE AND ITS CRYSTALLINE FORM, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| FR3011839B1 (fr) | Procede de preparation de derives d'acetamidophenyle | |
| FR3004181B1 (fr) | Procede de preparation de composes oxyboranes | |
| FR3010407B1 (fr) | Procede de preparation de derives oxysulfures et fluores par sulfination | |
| GB201315268D0 (en) | Process for preparation of blood group antigen derivatives | |
| PL398945A1 (pl) | Chiralne symetryczne sole imidazoliowe, pochodne alkoholu nasyconego oraz sposób ich wytwarzania |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |